The Show and After Show Previews the 2025 ASH Annual Meeting

In this special edition of The Show & After-Show, co-hosts Andrew Svonavec and Kristie Kahl are shaking things up—literally. Broadcasting away from their usual studio (and relying on some "high-tech" paper scripts), the duo breaks down everything oncology providers need to know before heading to the American Society of Hematology (ASH) Annual Meeting in Orlando.

ASH 2025 is set to be a landmark event for blood cancer research. As the field shifts toward curative intent, attendees should keep their eyes on several key areas:

• Targeted Therapies: Look for readouts on menin inhibitors, as well as FLT3 and IDH inhibitor combinations.
• Immunotherapy Evolution: A major focus will be on moving effective therapies, such as cellular and bispecific T-cell engagers, into earlier lines of treatment.
• Next-Gen Innovation: Expect data on "off-the-shelf" CAR T-cell therapies and BiTE therapy that challenge existing paradigms.
• Health Equity: Beyond the biology, sessions will address critical issues regarding financial toxicity, health disparities, and the integration of patient-reported outcomes.

“As we get ready to close out 2025, ASH is the meeting you don’t want to miss,” Kahl said. “Oncologists can look forward to a meeting that confirms the shift toward curative intent with next-generation cellular and gene-editing therapies, while simultaneously providing immediately actionable data on powerful novel combinations and strategies to deliver precision care to every patient.”

As part of the After Show, don’t forget there is plenty to do in Orlando outside of the theme parks. For dining, it is recommended to grab a porterhouse at STK Steakhouse in Disney Springs or Kres Chophouse on West Church. For a unique way to unwind, The Beer Spa is a venue where attendees can literally sit in a tub of hops while enjoying a cold drink.

Lastly, be sure to check out SCOUT, an AI-powered clinical assistant. It is designed to help clinicians quickly navigate guidelines, break down ASH data, and answer complex clinical questions using a database of expert-vetted oncology content.